Evidence map›Paper›PMID 31941095›Full record

ArticleViruses2020

Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics.

Travis Warren, Elizabeth Zumbrun, Jessica M Weidner, Laura Gomba, Franco Rossi, Roy Bannister, Jacqueline Tarrant, Matthew Reed, Eric Lee, Jo Lynne Raymond and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.4field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Travis WarrenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Elizabeth ZumbrunUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jessica M WeidnerUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Laura GombaUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Franco RossiUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Roy BannisterGilead Sciences, Foster City, CA 94404, USA.
Jacqueline TarrantGilead Sciences, Foster City, CA 94404, USA.
Matthew ReedUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Eric LeeUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jo Lynne RaymondUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jay WellsUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Joshua ShamblinUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Kelly WetzelUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Ginger DonnellyUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Sean Van TongerenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Nicole LackemeyerUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jesse SteffensUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Adrienne KimmelUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Carly GarveyUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Holly BloomfieldUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Christiana BlairGilead Sciences, Foster City, CA 94404, USA.
Bali SinghGilead Sciences, Foster City, CA 94404, USA.
Sina BavariUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Tomas CihlarGilead Sciences, Foster City, CA 94404, USA.
Danielle PorterGilead Sciences, Foster City, CA 94404, USA.
United States Army Medical Research Institute of Infectious Diseases · USGilead Sciences (United States) · USThe Geneva Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent Ebola virus (EBOV) outbreaks in West Africa and the Democratic Republic of the Congo have highlighted the urgent need for approval of medical countermeasures for treatment and prevention of EBOV disease (EVD). Until recently, when successes were achieved in characterizing the efficacy of multiple experimental EVD therapeutics in humans, the only feasible way to obtain data regarding potential clinical benefits of candidate therapeutics was by conducting well-controlled animal studies. Nonclinical studies are likely to continue to be important tools for screening and development of new candidates with improved pharmacological properties. Here, we describe a natural history study to characterize the time course and order of progression of the disease manifestations of EVD in rhesus monkeys. In 12 rhesus monkeys exposed by the intramuscular route to 1000 plaque-forming units of EBOV, multiple endpoints were monitored for 28 days following exposure. The disease progressed rapidly with mortality events occurring 7-10 days after exposure. Key disease manifestations observed consistently across the infected animals included, but were not limited to, viremia, fever, systemic inflammation, coagulopathy, lymphocytolysis, renal tubular necrosis with mineralization, and hepatocellular degeneration and necrosis.

Indexed as

Disease Models, AnimalAnimalsDisease ProgressionEbolavirusFemaleHemorrhagic Fever, EbolaInjections, IntramuscularMacaca mulattaMaleanimal modeldiseaseEbola virusEVDmacaquemonkeyrhesus

Identifiers

PMID31941095
PMCPMC7019527
OpenAlexW2999457729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.